Clinical Immunology Review Series: An approach to the patient with a periodic fever syndrome

Clinical and Experimental Immunology

Volumn 165, Issue 3, 2011, Pages 301-309

  Lachmann, H J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Human studies; Inflammation inflammatory mediators including eicosanoids; Tumour antigens

Indexed keywords

AUTOANTIBODY; COLCHICINE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN;

ABDOMINAL PAIN; AMYLOIDOSIS; ANALGESIA; BLAU SYNDROME; CINCA SYNDROME; CORTICOSTEROID THERAPY; DIARRHEA; DRUG MEGADOSE; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; INNATE IMMUNITY; LOW DRUG DOSE; OUTCOME ASSESSMENT; PAPA SYNDROME; PERIODIC FEVER SYNDROME; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RASH; RECURRENT DISEASE; REVIEW; SCHNITZLER SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; SYNDROME;

EID: 79961015780     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04438.x     Document Type: Review

References (68)

1. Consortium TFF. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17:25-31.
2. Consortium TIF. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997; 90:797-807.
3. Centola M, Wood G, Frucht DM etal. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000; 95:3223-31.
4. Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003; 31:282-5.
5. Touitou I, Lesage S, McDermott M etal. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004; 24:194-8.
6. Milhavet F, Cuisset L, Hoffman HM etal. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008; 29:803-8.
7. Lachmann HJ, Sengul B, Yavuzsen TU etal. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxf) 2006; 45:746-50.
8. Kone-Paut I, Hentgen V, Guillaume-Czitrom S, Compeyrot-Lacassagne S, Tran TA, Touitou I. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology 2009; 48:840-2.
9. Park HH, Lo YC, Lin SC, Wang L, Yang JK, Wu H. The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol 2007; 25:561-86.
10. Tidow N, Chen X, Müller C etal. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000; 95:1451-5.
11. Chae JJ, Wood G, Masters SL etal. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006; 103:9982-7.
12. Mikula M, Buller A, Sun W, Strom CM. Prevalence of known mutations in the familial Mediterranean fever gene (MEFV) in various carrier screening populations. Genet Med 2008; 10:349-52.
13. Livneh A, Langevitz P, Zemer D etal. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40:1879-85.
14. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287:1302.
15. Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A. The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci 2006; 10:173-8.
16. Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008; 153:1288-95.
17. Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003; 62:916-19.
18. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007; 13:38-40.
19. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine 2008; 75:504-5.
20. McDermott MF, Aksentijevich I, Galon J etal. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133-44.
21. Todd I, Radford PM, Daffa N, Bainbridge SE, Powell RJ, Tighe PJ. Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum 2007; 56:2765-73.
22. Rebelo SL, Bainbridge SE, Amel-Kashipaz MR etal. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006; 54:2674-87.
23. D'Osualdo A, Ferlito F, Prigione I etal. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54:998-1008.
24. Nedjai B, Hitman GA, Yousaf N etal. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:273-83.
25. Tchernitchko D, Chiminqgi M, Galacteros F etal. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 2005; 13:513-15.
26. Ravet N, Rouaghe S, Dode C etal. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65:1158-62.
27. Hoffmann LA, Lohse P, Konig FB, Feneberg W, Hohlfeld R, Kumpfel T. TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome. Neurology 2008; 70:1155-6.
28. Nowlan ML, Drewe E, Bulsara H etal. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxf) 2006; 45:31-7.
29. Gattorno M, Pelagatti MA, Meini A etal. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:1516-20.
30. van der Meer JW, Vossen JM, Radl J etal. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984; 1:1087-90.
31. Cuisset L, Drenth JP, Simon A etal. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 2001; 9:260-6.
32. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003; 60:1118-34.
33. Schneiders MS, Houten SM, Turkenburg M, Wanders RJ, Waterham HR. Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency. Arthritis Rheum 2006; 54:2306-13.
34. Simon A, Drewe E, van der Meer JW etal. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75:476-83.
35. Hoffmann GF, Charpentier C, Mayatepek E etal. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993; 91:915-21.
36. Houten SM, van Woerden CS, Wijburg FA, Wanders RJ, Waterham HR. Carrier frequency of the V377I (1129G>A) MVK mutation, associated with hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet 2003; 11:196-200.
37. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Balt) 1994; 73:133-44.
38. Houten SM, Frenkel J, Rijkers GT, Wanders RJ, Kuis W, Waterham HR. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002; 11:3115-24.
39. Ammouri W, Cuisset L, Rouaghe S etal. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology 2007; 46:1597-600.
40. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48:2645-51.
41. Lachmann HJ, Goodman HJ, Andrews PA etal. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis Rheum 2006; 54:2010-14.
42. Hoffman HM, Wright FA, Broide DH, Wanderer AA, Kolodner RD. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am J Hum Genet 2000; 66:1693-8.
43. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003; 4:95-104.
44. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 2004; 14:1929-34.
45. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348:2583-4.
46. Leslie KS, Lachmann HJ, Bruning E etal. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142:1591-7.
47. Muckle TJ, Wells MV. Urticaria, deafness and amyloidosis: a new heredo-familial syndrome. QJ Med 1962; 31:235-48.
48. Prieur AM, Griscelli C, Lampert F etal. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987; 66:57-68.
49. Hoffman HM, Throne ML, Amar NJ etal. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443-52.
50. Aksentijevich I, Masters SL, Ferguson PJ etal. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-37.
51. Wise CA, Gillum JD, Seidman CE etal. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11:961-9.
52. Blau EB. Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985; 107:689-93.
53. Miceli-Richard C, Lesage S, Rybojad M etal. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29:19-20.
54. Arostegui JI, Arnal C, Merino R etal. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56:3805-13.
55. Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987; 110:43-6.
56. Feder HM, Salazar JC. A clinical review of 105 patients with PFAPA (a periodic fever syndrome). Acta Paediatr 2010; 99:178-84.
57. Padeh S, Brezniak N, Zemer D etal. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 1999; 135:98-101.
58. Tasher D, Somekh E, Dalal I. PFAPA syndrome: new clinical aspects disclosed. Arch Dis Child 2006; 91:981-4.
59. Gattorno M, Caorsi R, Meini A etal. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009; 124:e721-8.
60. Garavello W, Romagnoli M, Gaini RM. Effectiveness of adenotonsillectomy in PFAPA syndrome: a randomized study. J Pediatr 2009; 155:250-3.
61. Peridis S, Koudoumnakis E, Theodoridis A, Stefanaki K, Helmis G, Houlakis M. Surgical outcomes and histology findings after tonsillectomy in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. Am J Otolaryngol 2010; 31:472-5.
62. Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Chronic urticaria, bone lesions, IgM macroglobulinemia - Waldenstroem disease. Bull Soc Française Dermatol Syphiligr 1974; 81:363.
63. de Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37:137-48.
64. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010; 5:38.
65. Pizzirani C, Falzoni S, Govoni M etal. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxf) 2009; 48:1304-8.
66. Lachmann HJ, Goodman HJ, Gilbertson JA etal. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361-71.
67. Lachmann HJ, Goodman HJB, Gilbertson JA etal. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361-71.
68. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35:745-53.